Skip to main content
S&P 5007,561.67-0.40%DOW52,347.55+0.10%NASDAQ25,136.27-0.91%BTC$68,258.00-3.68%ETH$1,927.42-4.09%GOLD$3,887.60+0.06%OIL$88.92+0.20%
Smart Investors Daily
SID Premium
Purple Biotech Ltd. logo

NASDAQ · PPBT

Purple Biotech Ltd.

Healthcare · Biotechnology

$1.63

Up+$0.07 (+4.49%)

Updated Nov 15, 2026, 5:38 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.26K
P/E ratio
-0.92
Dividend yield
0.00%
52-week range
$0.91 – $8.90
Volume
60.71K
Avg. volume
7.21M

Price performance · PPBT

PPBT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

PPBT closed at $1.63 after 20 trading sessions, up 50.93% for the selected period.

Last close
$1.63
Period change
+50.93%
Period low
$0.92
Period high
$1.63
Daily close
View OHLC price history
PPBT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.52$1.64$1.4101$1.6360.71K
Nov 12, 2026$1.46$1.56$1.361$1.5667.46K
Nov 11, 2026$1.33$1.49$1.28$1.4920.26K
Nov 10, 2026$1.30$1.38$1.22$1.3423.72K
Nov 9, 2026$1.24$1.35$1.20$1.3437.37K
Nov 6, 2026$1.15$1.33$1.15$1.3142.48K
Nov 5, 2026$1.34$1.34$1.16$1.2574.6K
Nov 4, 2026$1.16$1.22$1.0978$1.21553.54K
Nov 3, 2026$1.25$1.25$1.17$1.176.69K
Nov 2, 2026$1.17$1.23$1.16$1.2318.94K
Oct 30, 2026$1.09$1.17$1.07$1.1741.62K
Oct 29, 2026$1.01$1.09$0.999$1.0933.69K
Oct 28, 2026$0.93$0.96$0.91$0.957310.39K
Oct 27, 2026$1.00$1.02$0.917$0.92421.65K
Oct 26, 2026$1.08$1.08$1.0001$1.018.34K
Oct 23, 2026$1.03$1.09$1.02$1.0824.45K
Oct 22, 2026$1.15$1.15$1.05$1.0519.54K
Oct 21, 2026$1.09$1.15$1.09$1.1510.09K
Oct 20, 2026$1.08$1.13$1.08$1.08515.43K
Oct 19, 2026$1.15$1.15$1.0706$1.0840.31K

Latest PPBT news

The latest Smart Investors Daily articles mentioning PPBT.

Stock researchCompany · Overview

PPBT research

Overview

Company profile and research snapshot.

Company profile

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium

Yahoo · Sep 2, 2026

Top Midday Gainers

Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By